Work

Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab

Year: 2020

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2020.06.006

Authors: M.M. Hardesty, T. Krivak, G.S. Wright, E. Hamilton, E.L. Fleming, D. Gupta, E. Keeton, J. Chen, A. Clements, H.J. Gray, G.E. Konecny, R.G. Moore, D.L. Richardson

Institutions: Alaska Women's Cancer Care, Western Pennsylvania Hospital, Florida Cancer Specialists & Research Institute, Tennessee Oncology, Dartmouth–Hitchcock Medical Center, Dartmouth Cancer Center, Tesaro (United States), Riverside Methodist Hospital, University of Washington, University of California, Los Angeles, University of Rochester Medicine, University of Rochester, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4231567388

FWCI: 0.361

Cites:

Cited by: 4

Related to: 10